Keyphrases
Parkinson's Disease
100%
Functional Magnetic Resonance Imaging
38%
Ischemic Stroke
34%
Multiple System Atrophy
31%
Acute Stroke
29%
Transcranial Magnetic Stimulation
28%
Patients with Parkinson's Disease
28%
Randomized Controlled Trial
28%
Parkinson Patients
27%
Multiple Sclerosis
26%
Denmark
26%
Intracerebral Hemorrhage
26%
Transient Ischemic Attack
25%
Magnetic Resonance Imaging
22%
Hippocampus
21%
Schizophrenia
21%
Confidence Interval
21%
Healthy Controls
20%
Neurodegenerative Diseases
17%
Acute Ischemic Stroke
17%
Atrial Fibrillation
17%
Stroke Ischemic
16%
Spontaneous Intracerebral Hemorrhage
16%
Global Burden of Disease Study
15%
Cerebrospinal Fluid
15%
Alzheimer's Disease
15%
Prefrontal Cortex
15%
Amyotrophic Lateral Sclerosis
14%
Bipolar Disorder
14%
Number of Neurons
14%
Modified Rankin Scale
13%
Alpha-synuclein (α-syn)
13%
Brain Regions
13%
Transcranial Alternating Current Stimulation (tACS)
13%
Stroke Patients
13%
High Risk
13%
Advanced Parkinson's Disease
13%
White Matter
12%
Electroconvulsive Therapy
12%
Human Brain
12%
Tranexamic Acid
12%
Electroencephalography
12%
Stroke Trials
12%
Placebo
12%
Stereological Study
11%
Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD)
11%
Nitric Oxide
11%
Neural Response
11%
Deep Brain Stimulation
11%
Progressive multiple Sclerosis
11%
COVID-19
11%
Quality of Life
10%
Cortical Excitability
10%
Brain Activity
10%
Randomized Clinical Trial
10%
Erythropoietin
10%
Risk Factors
10%
Amygdala
10%
Glyceryl Trinitrate
10%
Older Adults
10%
Affective Disorders
9%
Glial Cells
9%
Copenhagen
9%
Magnetic Resonance Imaging Study
9%
Task Interdependence
9%
Whole Brain
9%
Cryptogenic Stroke
9%
Apomorphine Infusion
9%
Human Endogenous Retrovirus
9%
Supplementary Motor Area
9%
Cerebellum
9%
Functional Outcome
9%
Hand Motor Area
9%
Prospective Cohort Study
9%
Transcranial Direct-current Stimulation (tDCS)
9%
Cognitive Impairment
9%
Migraine
9%
Non-invasive Brain Stimulation
8%
Fractional Anisotropy
8%
Brain Response
8%
Serotonin 2A Receptor (5-HT2AR)
8%
Severe Traumatic Brain Injury (sTBI)
8%
Gray Matter Volume
8%
Working Memory
8%
Multiple Sclerosis Treatment
8%
Low Risk
8%
Medial Prefrontal Cortex (mPFC)
8%
Subthalamic nucleus
8%
Neuroimaging
8%
Odds Ratio
8%
Antipsychotics
8%
5-HT2A Receptor
8%
Thrombolysis
8%
Dyskinesia
8%
Antiplatelet Therapy
8%
Neurodegeneration
8%
Randomized Placebo-controlled Trial
8%
Clinical Outcomes
8%
Cortex
8%
Hematoma Expansion
8%
Neuroscience
Parkinson's Disease
93%
Brain Ischemia
37%
Functional Magnetic Resonance Imaging
37%
Multiple Sclerosis
32%
Dementia Praecox
31%
Transcranial Magnetic Stimulation
30%
Hippocampus
27%
Multiple System Atrophy
26%
Prefrontal Cortex
25%
Magnetic Resonance Imaging
24%
Cerebral Hemorrhage
23%
Magnetic Resonance Imaging
23%
Electrical Brain Stimulation
23%
Behavior (Neuroscience)
21%
Randomized Controlled Trial
16%
Cognitive Disorders
16%
Gray Matter
16%
Alzheimer's Disease
16%
Mood Disorder
15%
Bipolar Disorder
15%
In Vivo
14%
Electroencephalography
14%
Dopaminergic
14%
Neurodegenerative Disorder
13%
Placebo
13%
Transient Ischemic Attack
13%
Fractional Anisotropy
12%
Parkinsonism
12%
Excitability
12%
Working Memory
12%
Rapid Eye Movement Sleep
11%
Cognitive Function
11%
Face
11%
Glial Cells
11%
Amygdala
11%
Serotonin
10%
Nerve Potential
10%
Behavior Disorder
10%
5-HT2A Receptor
10%
Oligodendrocyte
10%
Transcranial Direct Current Stimulation
10%
Migraine
10%
Amyotrophic Lateral Sclerosis
10%
L-DOPA
10%
Nitric Oxide
9%
Gene Expression
9%
Motor Evoked Potential
9%
Dopamine Transporter
9%
Cerebellum
9%
Diffusion MRI
9%
Atrial Fibrillation
9%
Headache
9%
Striatum
9%
Axon
9%
Diffusion Tensor Imaging
9%
Microglia
9%
Motor Cortex
8%
Electroconvulsive Therapy
8%
Stereotypic Movement Disorder
8%
Frontal Lobe
8%
Transcranial Electrical Stimulation
8%
Erythropoietin
8%
Major Depressive Disorder
8%
In Vitro
8%
Stereology
8%
Glutamic Acid
7%
Neurodegeneration
7%
Positron Emission Tomography
7%
Prepulse Inhibition
7%
Subthalamic Nucleus
7%
Antithrombotic
7%
Neurotrauma
7%
Traumatic Brain Injury
7%
Eicosanoid Receptor
7%
Basal Ganglia
7%
Corpus Callosum
7%
Astrocyte
7%
Dementia with Lewy Bodies
7%
Supplementary Motor Area
7%
Primary Progressive Multiple Sclerosis
7%
Nuclear Magnetic Resonance Spectroscopy
7%
Positron Emission Tomography
6%
Functional Connectivity
6%
Iodine-123
6%
Dyskinesia
6%
Auras
6%
Rapid Eye Movement Sleep Behavior Disorder
6%
Dystonia
6%
Premotor Cortex
6%
Meta-Analysis
6%
Apomorphine
6%
Hematoma
6%
Anterior Cingulate Cortex
6%
Parvalbumin
6%
Ataxia
6%
Subarachnoid Hemorrhage
6%
Huntington's Disease
6%
Brain Areas
5%
Single-Photon Emission Computed Tomography
5%
Attention Deficit Hyperactivity Disorder
5%
Medicine and Dentistry
Apoplexy
99%
Brain Ischemia
44%
Parkinson's Disease
42%
Cerebral Hemorrhage
31%
Transient Ischemic Attack
25%
Symptom
22%
Magnetic Resonance Imaging
22%
Randomized Controlled Trial
21%
Atrial Fibrillation
17%
Disease
16%
Global Disease Burden
15%
Placebo
14%
Systematic Review
13%
Odds Ratio
11%
Adverse Event
10%
Parkinsonism
10%
COVID-19
10%
Modified Rankin Scale
10%
Prevalence
9%
Hematoma
9%
Nitric Oxide
9%
Cohort Analysis
9%
Injury
9%
Multiple Sclerosis
8%
Computer Assisted Tomography
8%
Clinical Trial
8%
Blood Clot Lysis
8%
Functional Magnetic Resonance Imaging
8%
Randomized Clinical Trial
8%
Quality of Life
8%
Transcranial Magnetic Stimulation
7%
Antiplatelet
7%
Shy-Drager Syndrome
7%
Drug Therapy
7%
Prospective Cohort Study
7%
Tranexamic Acid
7%
Glyceryl Trinitrate
6%
Computed Tomography Angiography
6%
Clinician
6%
Focused Ion Beam
6%
Infarction
6%
Blood Pressure
6%
Bleeding
6%
Headache
6%
Antithrombotic
6%
Migraine
5%
Disability Adjusted Life Years
5%
Hemodynamic
5%
Positron Emission Tomography
5%
Life Expectancy
5%
Paroxysmal Atrial Fibrillation
5%
Apomorphine
5%
Traumatic Brain Injury
5%
Progressive Supranuclear Palsy
5%
Diagnosis
5%
Cognition
5%